A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea

Study Overview
=================
Brief Summary
-----------------
To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment

Official Title
-----------------
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea

Conditions
-----------------
Rosacea

Intervention / Treatment
-----------------
* Drug: Azelaic Acid (Finacea Foam, BAY39-6251)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Diagnosis of rosacea by a medical professional Currently using Finacea Foam as topical monotherapy for rosacea Willing and able to provide voluntary, informed consent to participate in this study Exclusion Criteria: - Use of any other topical treatment for rosacea at the time of enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rosacea Concierge Program<br>Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam | Drug: Azelaic Acid (Finacea Foam, BAY39-6251)<br>* Finacea Foam, Active substance Azelaic acid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographics and clinical characteristics | Collected patient demographics and characteristics are : Year of birth Gender Insurance type | one-time survey in 2 week recruitment window | 
| Rosacea-relevant comorbidities and complications | Patient reported history of the following will be collected : Blepharitis Conjunctivitis Corneal neovascularization/keratitis Depression Migraine | one-time survey in 2 week recruitment window | 
| Rosacea subtype | Patient reported diagnosis of the following will be collected: Erythematotelangiectatic (facial redness) Papulopustular (bumps and pimples) Phymatous (enlargement of the nose) Ocular (eye irritation) Unknown | one-time survey in 2 week recruitment window | 
| Past use of topical rosacea treatments | Patient reported use of the following medications will be collected: Metronidazole gel Metronidazole cream Metronidazole lotion Metronidazole emulsion Brimonidine tartrate gel | one-time survey in 2 week recruitment window | 
| Patient concerns collected by Rosacea Treatment Preference Questionnaire | Rosacea Treatment Preference Questionnaire is a survey to assess patient self-reported rosacea subtype and severity, and to evaluate the concerns that contribute to patient satisfaction/dissatisfaction, as well as treatment decisions with rosacea topical treatments | one-time survey in 2 week recruitment window | 
| Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q) | SATMED-Q is a 17-question, validated, multidimensional generic questionnaire designed for use in patients with any chronic disease treated with medicines | one-time survey in 2 week recruitment window | 
| Quality of life measured by Dermatology Life Quality Index (DLQI) | DLQI is a widely used dermatology-related quality of life tool | one-time survey in 2 week recruitment window |